The severe asthma treatment "Pacenra" is available at general hospitals. According to related industries, Pacenra (or Fasenra, Benralizumab) of Astra Zeneca Korea has passed drug committee (DC) of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital , Ajou University Hospital, and Wonju Severance Christain Hospital.

Pacenra is approved for use as an additional treatment in adult patients with severe anaerobic asthma if it is not properly controlled by conventional treatment, and is then administered once every four weeks for the first three months.

One of the reason for asthma management is to reduce the risk